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Two hundred eighty methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates recovered from a
tertiary care hospital in Oporto, Portugal, between 2003 and 2005 were studied by a combination of molecular
typing techniques in order to investigate the genetic backgrounds associated with the changes in the resistance
phenotypes observed since 2001 and compare them to those previously found in the hospital. All MRSA isolates
were grouped into resistance profiles for a panel of seven antibiotics and characterized by pulsed-field gel
electrophoresis (PFGE) and SCCmec (staphylococcal cassette chromosomemec) typing. Representative isolates
of PFGE types were further studied by spa typing and multilocus sequence typing. Our findings clearly
document that the increasing isolation of nonmultiresistant MRSA strains was associated with the decline
(from 69% in 1996 to 2000 to 12% in 2003 to 2005) and massive replacement of the multiresistant Brazilian
clone (ST239-IIIA) by the epidemic EMRSA-15 clone (ST22-IV), in which resistance to antibiotics other than
-lactams is very rare, as the major clone (80% of isolates). The Iberian clone (ST247-IA), a major clone in
1992 to 1993, was represented in the present study by just one isolate. Two other pandemic MRSA clones were
detected, as sporadic isolates, for the first time in our hospital: the New York/Japan (ST5-II) and the
EMRSA-16 (ST36-II) clones. Furthermore, the pattern of susceptibility of MRSA isolates both to gentamicin
and to trimethoprim-sulfamethoxazole was shown to be an excellent phenotypic marker for the discrimination
of the EMRSA-15 clone from other nonmultiresistant MRSA clones present in our hospital.
Methicillin-resistant Staphylococcus aureus (MRSA) is cur-
rently the most commonly identified antibiotic-resistant noso-
comial pathogen worldwide (8, 19, 20, 58). The European
Antimicrobial Resistance Surveillance System reported an in-
crease from 16 to 24% between 1999 and 2004 (19) in the
overall prevalence of MRSA in all regions of Europe, including
countries of low endemicity. According to the most recent
report of the European Antimicrobial Resistance Surveillance
System, only 7 out of 30 countries still reported a prevalence of
MRSA below 3% in 2005, namely, Iceland, Norway, Sweden,
and Estonia, with a MRSA prevalence relatively stable over
time, and The Netherlands, Denmark, and Finland, with a
significant increase since 1999 (20). In summary, the central
European countries reported, in 2005, resistance prevalence
below 25%, whereas all southern European countries reported
higher levels and eight of them reported prevalence rates over
40%, including Portugal with a prevalence of 47% of invasive
MRSA isolates (20). However, in two southern European
countries, Slovenia and France, the implementation of appro-
priate long-term infection control measures has resulted in a
consistent decrease of the MRSA burden over the past 5 to 6
years, indicating that the control of MRSA in hospitals with
high prevalence is not an unachievable goal (20). Data regard-
ing the proportion of MRSA strains among all S. aureus iso-
lates identified at the Laboratory of Microbiology of Hospital
Geral de Santo Anto´nio (HGSA), Oporto, Portugal, since
1992 show that MRSA has been endemic in this hospital with
overall MRSA rates near 50% in the years 1992 through 1995.
In the following years, the MRSA rates decreased to around
43% in 2004 and then increased significantly to 55% in 2005.
The success of efforts in the control of MRSA transmission
within hospitals is largely determined by knowledge of the local
epidemiology, in particular the nature and number of clones
involved in carriage and infection and the identification of the
sources and vehicles of transmission, as well as the identifica-
tion of the reservoirs of epidemic clones in the population
and/or environment (9, 37, 38, 57).
Previous molecular typing of MRSA isolates recovered in
HGSA during two periods of surveillance revealed the same
scenario documented for several Portuguese hospitals, where
the Iberian clone (ST247-IA) was by 1992 and 1993 dominant,
represented by 77% of isolates, and drastically declined after
the introduction of the Brazilian clone (ST239-IIIA) in 1995.
The multidrug-resistant Brazilian clone was then repeatedly
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identified as the major clone in HGSA over the past several
years (1996 to 2000) (7).
The continuous-surveillance study of overall antibiotic resis-
tance in HGSA has shown, at least since 2001, a significant
change in the resistance profile of the MRSA isolates recov-
ered. MRSA strains in which resistance to antibiotics, other
than -lactams, was rare emerged more frequently, and at the
same time the traditional multiresistant MRSA strains became
less frequent. A similar trend of emergence and spread of
MRSA isolates with susceptibility to gentamicin (GEN) and
other antibiotics has been observed in hospitals in several
other European countries, namely, France, Germany, Bel-
gium, and Spain, among others (15, 16, 29, 30, 47, 61, 63).
In this study we characterized a collection of MRSA isolates
expressing the most frequent MRSA resistance profiles de-
tected in HGSA during a 3-year period (2003 to 2005) in order
to correlate the changes in the resistance profiles with the
clonal nature of MRSA in our institution and compare them
with those previously detected in 1992 to 1993 and 1996 to
2000 (7). A combination of molecular typing methods, includ-
ing pulsed-field gel electrophoresis (PFGE), spa typing, mul-
tilocus sequence typing (MLST), and SCCmec (staphylococcal
cassette chromosome mec) typing, was used to detect shifts in
the prevalence of major clones, the emergence of new epi-
demic clones, and the possible spread of previously detected
minor/sporadic clones.
MATERIALS AND METHODS
HGSA and wards/units included in the study. HGSA, Oporto, Portugal, is a
700-bed tertiary care teaching hospital with 26 wards; three intensive care units;
and 34 outpatient service units, including one specific diabetic foot unit and one
surgery unit. The numbers of patients hospitalized in 2003, 2004, and 2005 were
21,620, 22,208, and 24,282, respectively. In a retrospective analysis of data re-
garding the HGSA wards with the highest number of MRSA isolates, it was
observed that in the vascular surgery and endocrinology wards there was an
important rise of almost two-and-a-half- and fivefold, respectively, in the number
of MRSA strains isolated from 2001 to 2002. These wards are the major desti-
nation of diabetic foot outpatients when admitted to HGSA as inpatients and
were selected, together with the diabetic foot outpatient unit (DFOU) of HGSA,
for a preintervention study to better understand the epidemiology of MRSA
strains circulating in the hospital and their possible connections to the commu-
nity served by HGSA. In the vascular surgery ward 25 beds and 45 healthcare
workers (HCWs) were included, and in the endocrinology ward those figures
were 17 and 38, respectively. The DFOU of HGSA is a non-scheduled-appoint-
ment outpatient unit with a weekly average attendance of 120 diabetic patients
from northern Portugal. From January 2003 through December 2005 averages of
2,026 initial and 13,568 follow-up visits per year were recorded.
Clinical isolates. A total of 280 MRSA isolates representative of nasal colo-
nization samples (n  92) and infection samples (n  188) were included in the
present work; a single MRSA isolate per patient was studied. Colonization
screenings were performed during 1 week three times a year (February, June,
and November) in the three units included in this study. All admitted patients
and outpatients attending the DFOU during the week of the survey were
screened, and HCWs were also asked to participate. Also included in the colo-
nization collection were 10 strains isolated from patients and HCWs from a
high-risk-patient ward, the neonatal intensive care unit. One nasal swab (Cul-
turette EZ; Becton Dickinson) was taken from both anterior nares and tested for
the presence of S. aureus in the laboratory within 2 hours. Nasal swabs were
inoculated directly onto 5% sheep blood agar (bioMe´rieux, France) and manni-
tol salt agar plates (Biogerm, Portugal) and incubated for 24 to 48 h at 35°C;
colonies suspected to be S. aureus were tested with the Slidex StaphPlus agglu-
tination test (bioMe´rieux, France). Identification and susceptibility testing of all
S. aureus isolates were done with Vitek 2 system cards (bioMe´rieux, France).
MRSA isolates associated with infection were recovered from several clinical
sources, including pus (n  159), blood (n  14), tissue (n  4), bronchial
secretions (n  3), catheter (n  2), bone (n  1), urine (n  1), and other
diverse clinical sources (n  4).
The 280 MRSA isolates were recovered between 2003 and 2005 (85, 78, and
117 isolates in 2003, 2004, and 2005, respectively) from colonization or infection
samples of 255 patients (single MRSA isolates) and from colonization samples of
25 HCWs. The majority of isolates, 56% (146 out of 280), were recovered in the
vascular surgery ward, followed by DFOU with 30% (85 out of 280) and the
endocrinology ward with 14% (39 out of 280).
Antimicrobial susceptibility testing. The identification and antimicrobial sus-
ceptibility testing of MRSA isolates were performed with the Vitek 2 system
(cards GP and AST-P536, respectively) following the manufacturer’s recommen-
dations (bioMe´rieux, France). Inducible clindamycin (CLI) resistance was de-
tected using the disk approximation test according to CLSI guidelines, and the
phenotypes of resistance to macrolides, lincosamides, and type B streptogramins
(MLSB) were further assigned as follows: constitutive (cMLSB), erythromycin
(ERY) and CLI resistant; inducible (iMLSB), ERY resistant with CLI resistance
inducible by ERY (flattening of the CLI zone adjacent to the ERY disk); or M
phenotype, ERY resistant and CLI susceptible (no flattening of the CLI zone)
(12). MRSA isolates were further grouped into resistance profiles (RPs) accord-
ing to the pattern of susceptibility to a panel of seven antibiotics: GEN, ERY,
CLI, tobramycin (TOB), tetracycline (TET), rifampin (RIF), and trimethoprim-
sulfamethoxazole (SXT).
PFGE. PFGE was performed as described by Chung et al. (10) for all 280
isolates. The patterns obtained were interpreted by visual inspection according to
the criteria of McDougal et al. (31) and further deposited in a database and
analyzed with the Bionumerics software, version 4.6 (Applied-Maths, Kortrijk,
Belgium). PFGE patterns were identified using a dendrogram generated by the
unweighted-pair group method with arithmetic mean based on Dice coefficients,
where optimization and band position tolerance were set at 0.5 and 1.3%,
respectively. A similarity coefficient of 80% was selected to define the patterns
(31).
SCCmec typing and ccrAB typing. SCCmec typing was performed by a multi-
plex PCR strategy, previously described by Oliveira and de Lencastre (41), in
which a specific amplification pattern for each structural type of SCCmec is
generated. SCCmec type assignments were confirmed for a subset of 99 repre-
sentative strains by ccrAB typing as previously described by Okuma et al. (40).
Isolates classified as nontypeable or negative for ccrAB by PCR were selected for
ccrB sequencing, according to the work of Oliveira et al. (42).
spa typing and MLST. spa typing and MLST were performed as previously
described (14, 17, 27, 54). Sequences of both strands were determined at Mac-
rogen (Seoul, South Korea), and sequence analysis was carried out using DNAS-
tar software, version 5.07 (Lasergene, Madison, WI). Ridom StaphType soft-
ware, version 1.4 (Ridom GmbH, Wu¨rzburg, Germany), was also used for spa
type analyses. The new spa type assignments were obtained through the Ridom
SpaServer (http://spa.ridom.de/index.shtml). MLST sequence types were as-
signed through the MLST database (http://www.mlst.net).
Statistical analysis. Statistical analysis was performed with SPSS software,
version 15.0. The proportions were compared using the chi-squared test or
Fisher’s exact test, as appropriate. A P value of 0.05 was defined as statistically
significant; all statistical tests were two-tailed.
RESULTS
Phenotypic and genotypic characterization of MRSA iso-
lates. Of the 280 MRSA isolates studied, 10% were resistant to
GEN, 82.5% to ERY, 82.5% to CLI, 16.4% to TOB, 14.3% to
TET, 14.6% to RIF, and 12.8% to SXT. Among the 231 iso-
lates resistant to CLI, resistance was constitutive (cMLSB) in
63.2% (n  146) of isolates and inducible (iMLSB) in 36.8%
(n  85); no isolate showed the M phenotype.
The MRSA isolates were grouped into 12 RPs with the
majority belonging to RP-I (susceptibility to all antibiotics) and
RP-II (resistance to ERY and CLI) with 16% (46 out of 280)
and 64% (179 out of 280) of isolates, respectively (Table 1).
The remaining MRSA isolates were included in RP-III (resis-
tance to RIF), RP-IV (resistance to SXT), RP-V (resistance to
ERY, CLI, and TET), RP-VI (resistance to ERY, CLI, and
RIF), RP-VII (resistance to ERY, CLI, and TOB), RP-VIII
(resistance to ERY, CLI, TOB, and RIF), RP-IX (resistance to
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ERY, CLI, TET, RIF, and SXT), RP-X (resistance to all but
GEN), RP-XI (resistance to all but SXT), and RP-XII (resis-
tance to all antibiotics) (Table 1).
The 280 MRSA isolates were classified into nine PFGE
types: J (80.3%; n  225), B (11.8%; n  33), M (3.5%; n 
10), C (2.1%; n 6), D (0.7%; n 2), and A, E, F, and G, with
one isolate each (Table 2). The major type could be further
divided into 15 subtypes with the majority of the isolates (79%,
n  178) belonging to a single subtype (J189). PFGE pattern B
could be also divided into 15 subtypes with 36% of isolates (12
out 33) belonging to a single subtype (B234). Type M was
divided into three subtypes.
No correlation could be established between single resis-
tance profiles and PFGE types, since the same resistance pro-
file could be found among isolates presenting distinct PFGE
types (Table 1). Nevertheless, MRSA isolates belonging to the
major PFGE type J demonstrated a uniform susceptibility to
GEN and SXT and were all susceptible to TOB, RIF, and
TET, except for one, three, and four isolates, respectively; the
majority of the isolates (82%) were resistant to ERY and CLI
TABLE 1. Resistance profiles of the 280 MRSA strains studied and associated PFGE types
RP
Susceptibility toa: Total no.
of isolates
PFGE type(s)
(no. of isolates)GEN ERY CLI TOB TET RIF SXT
I S S S S S S S 46 J (40); M (5); E (1)
II S R R S S S S 179 J (178); M (1)
III S S S S S R S 1 J (1)
IV S S S S S S R 2 D (2)
V S R R S R S S 4 J (4)
VI S R R S S R S 1 J (1)
VII S R R R S S S 8 M (2); C (6)
VIII S R R R S R S 3 M (2); J (1)
IX S R R S R R R 1 B (1)
X S R R R R R R 7 B (7)
XI R R R R R R S 2 A (1); F (1)
XII R R R R R R R 26 B (25); G (1)
a MIC breakpoints, expressed in g/ml, used for the definition of categories of susceptible (S), intermediate (I), and resistant (R), were those recommended by CLSI:
GEN, 4, 8, and 16; ERY, 0.5, 1 to 4, and 8; CLI, 0.5, 1 to 2, and 4; TOB, 4, 8, and 16; TET, 4, 8, and 16; RIF, 1, 2, and 4; SXT, 2/38, —
(intermediate breakpoint not applicable to SXT per CLSI), and 4/76, respectively.
TABLE 2. Summary of the molecular typing data for 280 MRSA strains, January 2003 to December 2005, HGSA
PFGE type; no.
(%) of strains
SCCmec type; no.
of strains
Ridom spa typingb MLSTb
spa type Sequence of repeats Allelic profile STc
J; 225 (80.3) IV; 224
t032 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28
7-6-1-5-8-8-6 22
t747 26-23-23-31-29-17-31-29-17-25-17-25-16-28
t849 26-23-23-29-17-25-17-25-16-28
t022 26-23-13-23-31-29-17-31-29-17-25-17-25-16-28
IV vara; 1 t032 26-23-23-13-23-31-29-17-31-29-17-25-17-25-16-28
B; 33 (11.8) IIIA; 33 t037 15-12-16-02-25-17-24 2-3-1-1-4-4-3 239
M; 10 (3.5)
I; 4 t002 26-23-17-34-17-20-17-12-17-16 1-4-1-4-12-1-10 5
II; 1 t045 26-17-20-17-12-17-16
IV; 2
IVA; 3 t002 26-23-17-34-17-20-17-12-17-16 1-43-1-4-12-1-10 146t509 26-23-17-20-17-12-17-16
C; 6 (2.1) II; 6 t018 15-12-16-02-16-02-25-17-24-24-24 2-2-2-2-3-3-2 36
D; 2 (0.7) IV; 2 t186 07-12-21-17-13-13-34-34-33-34 22-1-14-23-12-4-31 88
A; 1 (0.4) IA; 1 t051 11-19-21-12-21-17-34-24-34-22-25 3-3-1-12-4-4-16 247
E; 1 (0.4) IVA; 1 t645 14-44-13-12-17-23-18-17 6-5-6-2-7-14-5 121
F; 1 (0.4) NTd; 1 t860 08-16-02-25-17 2-3-1-1-4-4-3 239
G; 1 (0.4) IIIA; 1 t021 15-12-16-02-16-02-25-17-24 2-3-1-1-4-4-3 239
a IV var, dcs negative, ccrAB type 2.
b spa typing and MLST were performed on representative strains of all PFGE types and subtypes.
c Clones correspond to sequence types as follows: EMRSA-15 clone, ST22-IV; Brazilian clone, ST239-IIIA; New York/Japan clone, ST5-II; pediatric clone, ST5-IV;
EMRSA-16 clone, ST36-II; Iberian clone, ST247-IA.
d NT, nontypeable.
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(57.6% with the constitutive phenotype and 42.4% with the
inducible phenotype) (Table 1). In contrast, 100% of MRSA
isolates associated with PFGE type B were resistant to ERY,
CLI, TET, RIF, and SXT, and all but one were resistant to
TOB; 87.9% of MRSA isolates resistant to CLI showed the
constitutive phenotype (cMLSB). A heterogeneous resistance
profile for GEN (76%; 25 out of 33) was observed (Table 1).
For the seven minor PFGE types found, which represented
8% (22 out of 280) of isolates, a greater heterogeneity in
resistance profiles was observed. Nevertheless, two general
groups could be distinguished: one with MRSA isolates resis-
tant to -lactams only or to -lactams plus one to three anti-
biotics (PFGE types C, D, E, and M) and a second group with
MRSA isolates resistant to all or nearly all seven antibiotics
(PFGE types A, F, and G) (Table 1).
Furthermore, no correlation could be established between
single PFGE types and the phenotypes of macrolide resistance,
though 91.8% (n  78) of MRSA isolates with the inducible
phenotype were characterized by PFGE type J, 4.7% (n  4)
by PFGE type B, and 3.5% (n  3) by PFGE type M.
spa typing, MLST, and SCCmec typing. spa typing and
MLST were performed on representative strains from each
group as defined by PFGE (Table 2). The predominant PFGE
type J was characterized by four different spa types (t022, t032,
t747, and t849), sequence type 22 (ST22), and SCCmec type IV
(clone ST22-IV, EMRSA-15), except for one strain classified
as a SCCmec type IV variant. PFGE type B isolates were
characterized by spa type t037, ST239, and SCCmec type IIIA
(clone ST239-IIIA, Brazilian). Two isolates, with closely re-
lated spa types (types t860 and t021) but unique patterns (types
F and G) were also characterized by ST239.
All the 10 PFGE type M isolates belong to clonal complex 5
(CC5) (ST5 or its single-locus variant ST146) and have closely
related spa types (t002, t045, and t509). However, four differ-
ent SCCmec types were detected (I, II, IV, and IVA), so that
these strains were assigned to different clonal types: the New
York/Japan clone (ST5-II), the pediatric clone (ST5-IV), and
clone ST146-IVA. ST146-IVA may have evolved from the pe-
diatric clone, resulting from a single point mutation (aroE
allele 43 43), plus the integration of pUB110 in the SCCmec
type IV cassette. This clone has been already described in
association with the hospital environment in Spain (47).
Molecular typing identified two other previously described
epidemic MRSA clones: EMRSA-16 (ST36-II) and the Iberian/
Archaic clone (ST247-I), which accounted for 2.1% (6 out of
280) and 0.4% (1 out of 280) of the isolates, respectively. Two
other clones, ST88-IV and ST121-IVA, were also found in two
strains and one strain, respectively.
SCCmec typing results of the 280 MRSA isolates are sum-
marized in Table 2. All isolates except one were assigned to a
SCCmec type based on the SCCmec multiplex strategy (41).
The single isolate nontypeable by the SCCmec multiplex strat-
egy did not present a typical pattern; despite the fact that some
amplifications were specific for SCCmec III, when ccrAB typing
was performed, only the control primers presented amplifica-
tion products (40). ccrAB typing was performed on 99 repre-
sentative isolates and confirmed the SCCmec type assignment
for all strains except two, previously assigned to SCCmec type
II by the multiplex strategy. The two strains nontypeable by
ccrAB typing were further evaluated by ccrB typing according
to the work of Oliveira et al. (42). One strain could not be
characterized either by ccrAB or by ccrB typing, and further
studies are needed in order to characterize the SCCmec type
present; ccrB typing results confirmed the SCCmec multiplex
result for the other strain.
DISCUSSION
Epidemiological studies using different molecular typing
techniques have demonstrated that most hospital-acquired
MRSA infections are due to a relatively small number of ep-
idemic MRSA clones spread worldwide, namely, the Iberian
(ST247-IA), the Brazilian/Hungarian (ST239-III), the Berlin
(ST45-IV), the New York/Japan (ST5-II), the pediatric (ST5-
IV), the EMRSA-15 (ST22-IV), and the EMRSA-16 (ST36-II)
clones (18, 43, 44).
Previous characterization of MRSA isolates recovered in
our hospital from two periods of surveillance allowed us to
detect important shifts in the clonal nature of endemic MRSA
in our hospital since 1992 (7). The most relevant change was
the replacement of the Iberian clone (ST247-IA) by the Bra-
zilian clone (ST239-IIIA) in the mid-1990s. Besides these two
multiresistant MRSA clones, which were also the most fre-
quent in several other Portuguese hospitals during the last
decade, minor or sporadic clones also with epidemic potential
were identified at HGSA, such as the pediatric clone (ST5-IV)
(22, 51).
Several molecular techniques are available for MRSA typ-
ing, allowing the discrimination of epidemiologically related or
clonal isolates from unrelated isolates. However, criteria for
the application of each technique will be different according to
the purpose of the study, dealing for example either with local
outbreak investigations or with large-scale surveillance studies
(55, 60). Although PFGE is a powerful technique for evaluat-
ing the relatedness of isolates for epidemiological purposes, it
might not be the best option for evolutionary studies. MLST
has been proven to be a typing tool suitable for long-term and
global epidemiology, allowing related MRSA strains recovered
over extended periods of time and different countries to be
readily identified (18). In our study the application of a com-
bination of methods such as PFGE, spa typing, MLST, and
SCCmec typing allowed us to better identify the clonal nature
of MRSA strains circulating in HGSA over 3 years (2003 to
2005) and compare them with those observed in 1992 to 1993
and 1996 to 2000.
Changes in the genetic background of MRSA isolates from
HGSA over time. Data regarding the MRSA prevalence among
all S. aureus isolates identified at the Laboratory of Microbi-
ology, HGSA, since 1992 show that MRSA has been endemic
in this hospital with an overall MRSA rate around 45% (min-
imum, 36%; maximum, 55%) for the last 14 years, without
significant changes over time. Nevertheless, the present study
has revealed major shifts in the clonal nature of these isolates,
namely, the massive replacement of the Brazilian clone
(ST239-IIIA, PFGE type B) by the EMRSA-15 (ST22-IV,
PFGE type J) clone as the major clone (80% of all the 280
MRSA isolates studied) in HGSA. As a matter of fact, the
Brazilian clone, which in 1996 to 2000 was the major clone
(69%) at HGSA, in 2003 to 2005 was represented by only 12%
of the MRSA strains isolated. The EMRSA-15 clone was
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found to be widely disseminated, with no statistically significant
difference, in the three wards and the outpatient unit evaluated
(P  0.61). Furthermore, no difference was observed concern-
ing the type of clinical sample (infection versus colonization;
P  0.73) or whether MRSA was recovered from patients or
HCWs (P  0.60). However, we found an interesting and
statistically significant association (P  0.005) of this clone
with patients who usually attend the DFOU versus those pa-
tients who do not attend the DFOU. Our findings support the
data recently published by Alcoceba et al. reporting the spread
of the EMRSA-15 clone more frequently among nonhospital-
ized patients (emergency room and outpatient departments)
than among hospitalized patients from the three main public
Majorcan hospitals (6). Nevertheless and despite the sugges-
tion by Alcoceba et al. about the movement of EMRSA-15
occurring mainly from the community to the hospital setting,
the MRSA isolates recovered from the outpatients attending
the DFOU were classified as hospital acquired since all of the
patients had had previous visits to the DFOU, an average of
four in the previous 12 months, and 70% had been previously
admitted as inpatients to HGSA. In contrast to the observa-
tions by Alcoceba et al., the proportion of the EMRSA-15
isolates among blood samples was not statistically different
from other samples (P  0.49), though 71.4% of MRSA iso-
lates from blood samples belonged to the EMRSA-15 clone;
nevertheless, further studies with a large number of blood
samples would be necessary to clarify this issue.
EMRSA-15 was first reported in 1991 in southeast England
and the Midlands, rapidly spread across a large number of
hospitals in the United Kingdom, and became one of the two
most dominant epidemic clones, accounting for 70% of MRSA
strains isolated in England and Scotland (25, 36, 48). The
EMRSA-15 clone is one of the pandemic MRSA clones (18)
and has been identified in several countries such as The Neth-
erlands (18, 62), Denmark (21), Germany (63), Ireland and
Sweden (18), the Czech Republic (32, 33), Australia and New
Zealand (23, 46), Kuwait (59), and Spain (6, 35, 47).
Another relevant finding of the present study concerns the
Iberian clone (ST247, SCCmec type IA, PFGE type A), which
almost disappeared from HGSA, being represented by just one
isolate. It is important to note that the Iberian clone was in
1992 to 1993 the major clone (77%) in HGSA, as well as in
several other Portuguese hospitals. With the emergence of the
Brazilian clone around 1996, the representation of the Iberian
clone drastically declined to 17% in our hospital during 1996 to
2000. Our results shows that the pediatric clone (ST5-IV,
PFGE type M), which was one of the minor clones (1.7% of
isolates) detected at HGSA in 1992 to 1993, was unable to
spread over time, remaining in 2003 to 2005 at a stable low
level (less than 2% of isolates).
Two other important pandemic MRSA clones were detected
for the first time in our hospital in 2005, the New York/Japan
(ST5-II, PFGE type M) clone and the EMRSA-16 (ST36-II,
PFGE type C) clone, represented by one and six isolates,
respectively. The New York/Japan clone was found to be a
predominant clone in the United States (31, 49, 50), Canada
(56), Japan (3), and Korea (26) and was also detected in
Finland, Ireland, and the United Kingdom (18). To our knowl-
edge, this is the first report of the New York/Japan clone in a
Portuguese hospital. An interesting observation was the heter-
ogeneity of SCCmec types associated with CC5 (ST5 and
ST146). Notwithstanding the fact that SCCmec types II to IV
have been already reported associated with ST5 (2), it is worth-
while to note that PFGE profile type M was first described in
HGSA in 2003 associated with ST146, a single-locus variant of
ST5, and SCCmec type IVA and that at the same time, a group
of methicillin-susceptible S. aureus strains, characterized by the
same PFGE profile and spa type but by ST5, were also isolated
in the same wards (data not shown). Since different SCCmec
types have been found associated with CC5 strains (ST5 and
ST146), we may be in the presence of multiple acquisitions of
the SCCmec (types I, II, IV, and IVA) by a single background
(CC5). The EMRSA-16 clone, initially associated with an out-
break in 1992 in Northamptonshire, United Kingdom, is now-
adays together with EMRSA-15 one of the major clones in the
United Kingdom, where the two are responsible for more than
95% of MRSA bacteremia (13, 25, 36). This clone was also
found in Mexico (4), Canada (56), and several European coun-
tries such as Greece (1); Sweden (53); Finland (52); Denmark,
Switzerland, and Belgium (39); and Spain (35, 47).
Recent studies from two hospitals in Tenerife, Spain, re-
ported the abrupt replacement, after 2000, of the Iberian clone
(ST247-IA) by EMRSA-16 (ST36-II) as the major clone (35,
47). The presence of the EMRSA-15 clone was also reported,
although it represented only 2 to 3% of MRSA isolates recov-
ered from these hospitals. A different picture was observed in
our hospital, where EMRSA-15 was shown to have a clear
advantage over EMRSA-16, which emerged later as a minor
clone (5% of isolates). However, future follow-up studies of
the clonal nature of MRSA in our hospital will allow us to trace
the spread of EMRSA-16, which seems to have the same ep-
idemicity as the EMRSA-15 clone as shown in hospitals in the
United Kingdom and other European countries.
Clone ST88-IV, which has been already reported in Asia
(26) and associated with community-associated MRSA strains
in Switzerland (24), was also identified in our study. Although
only two strains were found, both were from the same ward,
one isolated from a newborn (blood) and the other from an
HCW (nasal swab). Although the two strains were not isolated
at the same time, this may demonstrate a possible route for
colonization/infection in the hospital due to the HCWs, since
no other ST88-IV strains were found during the study period.
Similar observations were already made in previous studies
(11, 34).
Clone ST121 has been most often associated with methicil-
lin-susceptible S. aureus from carriage, as previously described
(5, 28), and according to the data available at the MLST
database (http://www.mlst.net). However, in our study we iden-
tified a single ST121 MRSA strain. An ST121 MRSA strain,
isolated from sputum, was also identified in a Chinese hospital
in 2006 (http://www.mlst.net), and another ST121-IV MRSA
strain, associated with nasal carriage, was detected in 2005 in
the United States (45). The emergence in our hospital of
ST121 MRSA strains may be a result of a local and recent
SCCmec acquisition by a susceptible S. aureus background.
Relationship between the narrowing of resistance pheno-
types and the spread of new epidemic clones. In contrast with
MRSA strains isolated in HGSA during the last decade (1990
to 2000), which were typically multiresistant, a significant
change was observed, at least since 2001, with the increasing
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isolation of MRSA strains susceptible to multiple antibiotics
such as GEN, SXT, TOB, TET, and RIF. The proportion of all
MRSA strains isolated in HGSA that were resistant to these
antibiotics drastically decreased from 2001 to 2005, as shown in
Fig. 1. Our data revealed an excellent correlation between the
susceptibility both to GEN and to SXT and the EMRSA-15
clone (ST22-IV), as 100% of MRSA strains of this clone were
susceptible to those antibiotics. Globally, 86% (242 out of 280)
of all MRSA isolates were susceptible to GEN and SXT, with
93% (225 out of 242) of these belonging to PFGE type J; the
remaining 7% were distributed among three minor clones
(PFGE types C, M, and E). Furthermore, the great majority of
EMRSA-15 isolates were shown to be susceptible to other
antibiotics, namely, TOB (224 out of 225 isolates), RIF (222
out of 225), and TET (221 out of 225). The data presented here
document that the observed changes in the resistance pheno-
types of MRSA isolates recovered in HGSA since 2001 have
been directly associated with the epidemic spread of the
EMRSA-15 clone within the institution.
Our findings confirmed the susceptibility patterns observed
by others for EMRSA-15, which is commonly susceptible to
GEN, TET, and RIF, among other antibiotics, but with the
great majority of isolates resistant to CIP, ERY, and CLI (6,
63). The most frequent MLSB phenotype detected was the
constitutive (cMLSB) phenotype expressed by almost 60% of
the EMRSA-15 isolates resistant to CLI, in contrast with data
recently published by Alcoceba et al. (iMLSB phenotype in
67% of isolates) (6). Resistance to SXT was confirmed to be an
important phenotypic marker for the identification of the Bra-
zilian clone (ST239, SCCmec type IIIA, PFGE type B) among
the multiresistant MRSA isolates, since 92% (33 out of 36) of
the MRSA isolates found to be resistant to SXT presented
PFGE type B. Therefore, the decrease in the number of
MRSA isolates resistant to SXT observed at HGSA, at least
since 2001, is related to the replacement of the Brazilian clone
by EMRSA-15, which is susceptible to SXT, as the major clone
in HGSA.
In this study, we characterized, by a combination of molec-
ular typing techniques, a collection of MRSA isolates to inves-
tigate the genetic backgrounds associated with the changes in
the resistance phenotypes of MRSA isolates from a Portuguese
hospital during a 3-year period. Our results clearly document
that the decrease of resistant traits of MRSA strains isolated in
HGSA is associated with the decline and replacement of the
multiresistant Brazilian clone (ST239-III) as the major MRSA
clone until 2000 and the astonishing spread of the epidemic
EMRSA-15 (ST22-IV) clone, at least since 2003, in which
resistance to antibiotics other than -lactams is very rare. Fur-
thermore, the pattern of susceptibility of MRSA isolates to
both GEN and SXT was shown to be an excellent phenotypic
marker for the identification and discrimination of the
EMRSA-15 clone from other nonmultiresistant MRSA clones
present in our hospital. We believe that EMRSA-15 emerged
in our institution around 2001, attesting to the significant
changes in the resistance phenotypes of MRSA isolates ob-
served, though a single-locus variant of ST22, the allelic profile
ST79, was previously identified in 2000. The finding that the
overwhelming majority (80%) of MRSA isolates recovered
from infection and colonization samples, from patients and
HCWs, belonged to the EMRSA-15 clone, mainly to only one
PFGE subtype that was found among 79% of the EMRSA-15
isolates, emphasizes its epidemic nature and remarkable suc-
cess in spreading within an institution. These results enhanced
our understanding of the epidemiology of MRSA in the se-
lected wards in terms of reservoirs and routes of transmission,
providing valuable information for the development of inter-
vention strategies to control MRSA infections. An additional
finding of this study of interest and concern was the high
prevalence of the EMRSA-15 clone (77%) among the MRSA
isolates recovered from the nasal samples of outpatients at-
tending the DFOU, who may represent an important reservoir
and vector for MRSA dissemination within the hospital, when
admitted as inpatients and most likely within the community.
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